Bivalirudin, thrombin and platelets: Clinical implications and future directions

Journal of Invasive Cardiology

Volumn 15, Issue 8 SUPPL., 2003, Pages 1-15

  Becker, Richard ^b   Butenas, Saulius ^b   Carr Jr , Marcus ^b   Jaffer, Farouc ^b   Kleiman, Neal S ^b   Marmur, Jonathan D ^b   Schneider, David J ^b   Spiess, Bruce D ^a   Steinhubl, Steven R ^b   Weitz, Jeffrey I ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ARGATROBAN; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; MELEGATRAN; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTERY INJURY; BLEEDING; BLOOD CLOTTING; CLINICAL PATHWAY; CLINICAL TRIAL; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EXPERIMENTAL MODEL; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TIME SERIES ANALYSIS;

EID: 0041737663     PISSN: 10423931     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 1:1258-63.
2. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and Provisional Glycoprotein IIb/lIIa Blockade compared with Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention. REPLACE-2 Randomized Trial. JAMA 2003;289:853-63.
3. Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964;145:1310-12
4. MacFarlane RG. An enzyme cascade in the blood clotting mechanism and its function as a biological amplifier. Nature 1964;202:498-9
5. Mann KG. Biochemistry and physiology of blood coagulation Thromb Haemost 1999;82(2):165-74.
6. Brummel KE, Paradis SG, Butenas S, Mann KG. Thrombin functions during tissue factor-induced blood coagulation release and factor XIII activation. Blood 2002;100:148-52.
7. Monroe DM. Platelets and thrombin generation. AVHB 2002;22:1381-9.
8. Ashby B CR, Daniel JL, Kunapuli SP, Smith JB. Platelet stimulatory and inhibitory receptors. In: Colman RW (ed). Hemostasis and Thrombosis, Fourth Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:505-20.
9. Colman R, Clowes, A, James, G. Overview of hemostasis. In: Colman RW (ed). Hemostasis and Thrombosis, Fourth Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:3-16.
10. Ferguson JJ, Waly HM, Wilson JM. Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. Am Heart J 1998;135:S35-42.
11. Derian CK, Damiano MR, Andrade-Gordon P. Thrombin regulation of cell function through protease-activated receptors: Implications for therapeutic intervention. Biochemistry 2002;67(1):56-64.
12. Ashby B CR, Daniel JL, Kunapuli SP, Smith JB. Platelet stimulatory and inhibitory receptors. In: Colman RW (ed). Hemostasis and Thrombosis, Fourth Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:505-20.
13. Ofusu F. Protease activated receptors 1 and 4 govern the responses of human platelets to thrombin. Transfusion and Apheresis and Science 2003;28:265-8.
14. Sambrano GR, Weiss EJ, Zheng Y, et al. Role of thrombin signaling in platelets in haemostasis and thrombosis. Nature 2001;413:74-8.
15. Derian CK, Damiano BP, Addo MF, Darrow AL, et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. JPET 2003;304:855-61.
16. Mutch NJ, Robbie LA, Booth NA. Human thrombi contain an abundance of active thrombin. Thromb Haemost 2001;86(4):1028-34.
17. Becker DL, Fredenburgh JC, Stafford AR, Weitz JI. Exosites 1 and 2 are essential for protection of fibrin-bound thrombin from heparin-catalyzed inhibition by antithrombin and heparin cofactor II J Biol Chem 1999;274(10):6226-33.
18. Michalski R. Comparison of heparin and semi-synthetic heparin analogue, A73025, II: Some effects on platelet function. Br J Haematol 1977;37:247-55.
19. Salzman EW, Rosenberg RD, Smith MH, et al. Effect of heparin and heparin fractions on platelet aggregation. J Clin Investig 1980;65:64-73
20. Kabbani SS, Watkins MW, Holoch PA, et al. Platelet reactivity in coronary ostial blood: A reflection of the thrombotic state accompanying plaque rupture and of the adequacy of antithrombotic therapy. J Thromb Thrombolysis 2001;12(2):171-6.
21. Kabbani SS, Watkins MW, Ashikaga T, et al. Platelet reactivity characterized prospectively: A determinant of outcome 90 Days after percutaneous coronary intervention Circulation 2001;104:181-86.
22. Furman MI, Kereiakes DJ, Krueger LA, et al. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J 2001;142:790-8.
23. Chong BF, Ismail F. The mechanism of heparin-induced platelet aggregation. Eur. J Hematol 1989;43:245-51.
24. Storck J, Hollger N, Zimmermann RE. The influence of heparin and protamine sulfate on platelet ADP an platelet factor 4 release and the expression of glycoprotein IIb/IIIa. Hemostasis 1994;24:358-63.
25. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-6.
26. Sobel M. Heparin modulates integrin function in human platelets. J Vasc Surg 2001;33:587-94.
27. Direct Thrombin Inhibitor Trialists Collaboration Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Lancet 2002;359:294-302.
28. Tam SW, Fenton JW II, Detwiler TC. Disassociation of thrombin from platelets by hirudin. Evidence for receptor processing. J Biol Chem 1979;254(18):8723-5.
29. Goto S. Private communication.
30. Marmur J. Private communication.
31. Granger CB, Miller JM, Bovll EG et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995;91:1929-35.
32. Oltrona L, Eisenberg PR, Lasala JM, et al. Association of heparin-resistant thrombin activity with acute ischemic complications of coronary interventions. Circulation 1996;94:2064-71.